Daily Cardiology Research Analysis
Analyzed 243 papers and selected 3 impactful papers.
Summary
Three impactful cardiology papers stand out today: a preclinical small-molecule (BT2) given before reperfusion dramatically reduced infarct size and suppressed heart-failure–predictive gene programs in rats. In patients with chronic limb-threatening ischemia, a randomized trial showed a drug-eluting resorbable scaffold sustained superior patency and fewer reinterventions vs angioplasty at 3 years. Finally, an AI model using 12-lead ECG predicted 10-year ischemic stroke risk across health systems, capturing atrial cardiopathy signals.
Research Themes
- Preemptive cardioprotection and multi-omics modulation of post-ischemic remodeling
- Long-term endovascular therapy outcomes in infrapopliteal chronic limb-threatening ischemia
- AI-enabled ECG risk stratification for long-term ischemic stroke via atrial cardiopathy signals
Selected Articles
1. Preemptive cardioprotection with a small molecule in rodents that suppresses genes predictive of heart failure.
In rats subjected to ischemia–reperfusion, pre-reperfusion dosing of the small-molecule BT2 cut infarct size by ~70%, preserved function up to 2 weeks, and limited adverse remodeling and scarring. Single-nucleus and bulk RNA-seq showed BT2 suppresses inflammatory and fibrotic programs—particularly in macrophages and myofibroblasts—and downregulates rodent cardiac genes that predict heart failure in human ACS.
Impact: This study introduces a preemptive, transcriptomically validated strategy to blunt reperfusion injury and downstream heart-failure trajectories, with a mechanistic bridge to human ACS biology.
Clinical Implications: If safety and timing can be optimized, pre-PCI administration of a targeted kinase inhibitor could become a viable adjunct in high-risk unstable angina/NSTE-ACS or elective PCI to limit reperfusion injury and adverse remodeling.
Key Findings
- Pre-reperfusion BT2 reduced infarct size by approximately 70% in rats and preserved cardiac function at 24 hours and 2 weeks.
- BT2 prevented adverse left ventricular remodeling and scarring.
- snRNA-seq and bulk RNA-seq showed suppression of inflammation, fibrosis, and matrix genes, particularly in macrophages and myofibroblasts.
- Reduced macrophage and neutrophil infiltration following BT2.
- BT2 downregulated rodent cardiac genes predictive of HF in human ACS (e.g., cytokines, inflammasome components, DAMPs).
Methodological Strengths
- In vivo ischemia–reperfusion model with robust functional and histological endpoints over acute and subacute time points.
- Integrated multi-omics (snRNA-seq and bulk RNA-seq) linking cellular programs to phenotypic protection.
Limitations
- Preclinical rodent study; translational efficacy and safety in humans remain unknown.
- Preemptive dosing 24 hours before ischemia may be impractical for spontaneous STEMI; applicability likely limited to NSTE-ACS or elective PCI.
- Potential off-target effects of MAPK/ERK pathway inhibition not fully characterized.
Future Directions: First-in-human dose–timing studies in high-risk NSTE-ACS/elective PCI, biomarker-guided selection using inflammatory/fibrotic signatures, and safety profiling of MAPK/ERK modulation.
Ischemic heart disease is a leading cause of death worldwide. While percutaneous coronary intervention (PCI) restores blood flow in acute coronary syndrome (ACS), reperfusion injury exacerbates myocardial damage, contributing to heart failure (HF). Preemptive administration of a cardioprotective agent could help counter the imminent proinflammatory insult of PCI and reperfusion. Administering BT2, a small-molecule MAPK kinase/extracellular signal-regulated kinase inhibitor, 24 hours before and during ischemia in rats before reperfusion reduced infarct size by ~70% and preserved cardiac function 24 hours and 2 weeks postinjury. BT2 prevented adverse left ventricular remodeling and scarring. Single nucleus RNA sequencing (snRNA-seq) and bulk RNA-seq revealed that BT2 modulated genes associated with inflammation, fibrosis, and matrix production, especially within macrophages and myofibroblasts. BT2 suppressed macrophage and neutrophil infiltration. BT2 reduced the expression of genes in rodent hearts predictive of HF in patients with ACS, including many encoding cytokines, inflammasome components, and damage-associated molecular patterns. BT2 is a small molecule that can prevent myocardial ischemia-reperfusion injury, improve heart function, reduce cardiac fibrosis, and favorably modulate multiple key genes and biological processes in rats prognostic of HF when delivered before reperfusion. This strategy could be evaluated with high-risk unstable angina/non-ST-segment elevation myocardial infarction patients or those having an elective PCI.
2. Long-Term Outcomes of a Drug-Eluting Resorbable Scaffold vs Angioplasty in Infrapopliteal Chronic Limb-Threatening Ischemia: 3-Year Results From the LIFE-BTK Trial.
In 261 patients with infrapopliteal CLTI, randomized 2:1, the drug-eluting resorbable scaffold achieved higher 3-year freedom from the composite efficacy endpoint than angioplasty, with lower restenosis and fewer reinterventions, while limb salvage and safety were comparable. Multivariable analysis showed DRS independently reduced the hazard of CD-TLR (HR 0.46).
Impact: Provides rare 3-year randomized evidence in infrapopliteal CLTI demonstrating durable patency benefits of a resorbable scaffold over PTA, informing device selection in a difficult vascular bed.
Clinical Implications: In appropriately selected CLTI patients with infrapopliteal disease, a drug-eluting resorbable scaffold may reduce restenosis and reinterventions long-term without compromising limb salvage or safety, supporting its use where anatomy permits.
Key Findings
- 3-year efficacy endpoint favored DRS over PTA (59.5% vs 44.8%; P=0.0025).
- Binary restenosis lower with DRS (38.0% vs 49.0%); CD-TLR numerically lower (10.2% vs 18.4%).
- Limb salvage and primary safety endpoints were comparable (≈94% safety, ≈94–96% limb salvage).
- DRS independently reduced hazard of CD-TLR at 3 years (HR 0.46, 95% CI 0.22–0.97).
- Benefits were generally consistent across patient and lesion subgroups.
Methodological Strengths
- Randomized controlled design with prespecified composite endpoints and 3-year follow-up.
- Multivariable Cox modeling and subgroup analyses support robustness of findings.
Limitations
- Only 57% completed 3-year follow-up, which may introduce attrition bias.
- Device trial without blinding; generalizability depends on lesion/anatomical suitability.
Future Directions: Head-to-head comparisons with other contemporary devices, cost-effectiveness analyses, and strategies to improve follow-up completeness; evaluation in broader CLTI phenotypes.
BACKGROUND: Chronic limb-threatening ischemia (CLTI) caused by infrapopliteal disease is a major therapeutic challenge, with percutaneous transluminal angioplasty (PTA) associated with high rates of restenosis and reintervention. The LIFE-BTK trial previously demonstrated superior efficacy of the Esprit (Abbott Vascular) BTK drug-eluting resorbable scaffold (DRS) over PTA at 1 year, with sustained benefits at 2 years, with comparable safety at both time points. This report presents the 3-year outcomes. OBJECTIVES: We aimed to compare the 3-year safety and efficacy of DRS vs PTA in patients with CLTI and infrapopliteal artery disease. METHODS: In this randomized trial, 261 patients with CLTI were assigned 2:1 to DRS or PTA. The primary efficacy endpoint was freedom from above-ankle amputation in the target limb, target vessel occlusion, clinically driven target lesion revascularization (CD-TLR), and binary restenosis of the target lesion. The primary safety endpoint was freedom from major adverse limb events and perioperative death. RESULTS: A total of 57% of patients completed the 3-year follow-up. By Kaplan-Meier analysis, the 3-year primary efficacy endpoint was higher with DRS than PTA (59.5% vs 44.8%; P = 0.0025), binary restenosis occurred less frequently with DRS (38.0% vs 49.0%), and CD-TLR was numerically lower with DRS (10.2% vs 18.4%). Limb salvage remained high and comparable (93.8% vs 95.7%), as did the primary safety endpoint (90.8% vs 94.2%). In multivariable Cox regression at 3 years, treatment with DRS was associated with a lower hazard of CD-TLR compared with PTA (HR: 0.46 [95% CI: 0.22-0.97]), with previous minor amputation, greater preintervention stenosis, higher residual stenosis after predilatation, and use of postprocedure dual antiplatelet therapy being independent predictors of CD-TLR. Subgroup analyses showed that outcomes generally favored DRS for patency and reintervention across most patient and lesion characteristics. CONCLUSIONS: At 3 years, DRS demonstrated sustained advantages over PTA in preserving vessel patency, with lower restenosis and fewer reinterventions while maintaining a comparable safety profile. These findings support the use of DRS in selected patients with CLTI and infrapopliteal disease. (Pivotal Investigation of Safety and Efficacy of Drug-Eluting Resorbable Scaffold Treatment-Below the Knee [LIFE-BTK]; NCT04227899).
3. ECG Signatures and Long-Term Ischemic Stroke Risk: A Deep Learning Analysis of 200,000 Patients.
A deep learning model trained on 12-lead ECG predicted 10-year ischemic stroke with AUC ~0.77–0.80 across 3 health systems and calibration errors ≤0.03, performing similarly to the Framingham score. Saliency analyses focused on P-wave features, and risk was strongly associated with cardioembolic but not noncardioembolic stroke, consistent with an atrial substrate mechanism.
Impact: Demonstrates externally validated AI risk prediction of long-term stroke from routine ECG, linking signals to atrial cardiopathy and suggesting scalable screening to prioritize prevention.
Clinical Implications: ECG-based AI could augment conventional risk scores to identify individuals at cardioembolic stroke risk—potentially informing ambulatory rhythm monitoring, anticoagulation evaluation, or lifestyle interventions pending prospective validation.
Key Findings
- Model discrimination: 10-year AUC ~0.795 (MGH), 0.774 (BWH), 0.772 (BIDMC) with low calibration error (ICI ≤0.03).
- Performance comparable to revised Framingham Stroke Risk Profile across test cohorts.
- Saliency maps and correlations implicated P-wave features; model associated with cardioembolic but not noncardioembolic stroke (cause-specific HR 2.17 per 1-SD).
- Risk stratification held across subgroups, including patients with and without atrial fibrillation.
Methodological Strengths
- Large-scale development with external validation across independent health systems.
- Explainability via saliency and linkage to structured ECG features; robust calibration.
Limitations
- Retrospective observational design; prospective impact on outcomes untested.
- Potential domain shift across devices/sites and unmeasured confounding; clinical integration pathways require evaluation.
Future Directions: Prospective implementation trials to test decision impact and outcomes, fairness/performance across diverse populations and devices, and integration with AF screening strategies.
BACKGROUND: Scalable risk stratification for ischemic stroke remains an unmet need. OBJECTIVES: In this study, the authors sought to assess whether deep learning of 12-lead electrocardiograms (ECGs) can estimate longitudinal ischemic stroke risk and quantify the extent to which risk signals reflect plausible mechanisms (eg, atrial cardiopathy). METHODS: We trained a convolutional neural network to estimate the 10-year risk of incident ischemic stroke with the use of 12-lead ECG among patients receiving longitudinal care at Massachusetts General Hospital (MGH). Neural network-derived stroke probabilities, age, and sex were integrated into a Cox proportional hazards model ("ECG2Stroke"). Within an MGH test set ("MGH Test"), as well as independent samples from Brigham and Women's Hospital (BWH) and Beth Israel Deaconess Medical Center (BIDMC), we assessed model discrimination (area under the curve [AUC]) and calibration (integrated calibration index [ICI]). ECG2Stroke was compared with the revised Framingham Stroke Risk Profile (FSRP). Saliency mapping, associations with clinical factors and structured ECG features, and performance across stroke subtypes were assessed. RESULTS: ECG2Stroke was developed in 101,496 individuals from MGH (age 57 ± 16 years, 48% women), and evaluated in MGH Test (n = 4,771; age 57 ± 16 years, 49% women), BWH (n = 68,884; age 57 ± 16 years, 55% women), and BIDMC (n = 29,882; age 56 ± 17 years, 54% women). At 10 years, there were 346 stroke events in MGH Test, 3,209 in BWH, and 1,236 in BIDMC. ECG2Stroke demonstrated moderate discrimination of incident stroke (10-year AUCs: MGH Test, 0.795; BWH, 0.774; BIDMC, 0.772) and low calibration error (ICIs: MGH Test, 0.030; BWH, 0.005; BIDMC, 0.026). In patients with available data, 10-year AUC for ECG2Stroke was similar to FSRP (MGH/BWH Test: ECG2Stroke, 0.791; FSRP, 0.779; BIDMC: ECG2Stroke, 0.745; FSRP, 0.728). Stratification persisted across subgroups, including patients with and without atrial fibrillation. Saliency maps highlighted the ECG P-wave, and risk estimates correlated with structured P-wave indices. ECG2Stroke was strongly associated with cardioembolic stroke (cause-specific HR: 2.17 per 1-SD of logit-transformed probability; 95% CI: 1.64-2.87) but not noncardioembolic stroke. CONCLUSIONS: ECG-based artificial intelligence (AI) can predict 10-year ischemic stroke with performance similar to a validated clinical score, possibly by encoding markers of abnormal atrial substrate linked to cardioembolism. AI-enabled ECG analysis may enable efficient prioritization for stroke prevention.